NCT-04410796

A phase 2 randomized study of osimertinib versus osimertinib plus chemotherapy for patients with metastatic EGFR-mutant lung cancers that have detectable EGFR mutant cfDNA in plasma after initiation of osimertinib treatment

It's a Phase 2 trial comparing osimertinib alone to osimertinib with chemotherapy for people with advanced lung cancer that has a certain genetic change with an EGFR mutation. They're looking specifically at those whose blood shows an EGFR mutation. 

Phase 2: An advanced point of testing, where they're trying to confirm if a treatment works well.

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

EGFR: Epidermal Growth Factor Receptor (EGFR) is on the surface of cells and helps them grow and divide. In cancer, EGFR is like a switch that gets stuck in the "on" position, making cells grow and divide too much.

mutation: Mutation is an alteration in the genetic material of a cell or a virus that can be inherited by its descendants

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04410796

Clinical Trial Site: Columbia

To see all available clinical trials click here.